Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Authors:
- Justin BeardsleyJBJustin Beardsley
- Marcel WolbersMWMarcel Wolbers
- Freddie M. KibengoFKFreddie M. Kibengo
- Abu-Baker M. GgayiAGAbu-Baker M. Ggayi
- Anatoli KamaliAKAnatoli Kamali
- Ngo Thi Kim CucNCNgo Thi Kim Cuc
- Tran Quang BinhTBTran Quang Binh
- Nguyen Van Vinh ChauNCNguyen Van Vinh Chau
- Jeremy FarrarJFJeremy Farrar
- Laura MersonLMLaura Merson
- Lan PhuongLPLan Phuong
- Guy ThwaitesGTGuy Thwaites
Top Cited Papers
- 11 February 2016
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 374 (6) , 542-554
Abstract
Cryptococcal meningitis associated with human immunodeficiency virus (HIV) infection causes more than 600,000 deaths each year worldwide. Treatment has changed little in 20 years, and there are no imminent new anticryptococcal agents. The use of adjuvant glucocorticoids reduces mortality among patients with other forms of meningitis in some populations, but their use is untested in patients with cryptococcal meningitis. In this double-blind, randomized, placebo-controlled trial, we recruited adult patients with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi. All the patients received either dexamethasone or placebo for 6 weeks, along with combination antifungal therapy with amphotericin B and fluconazole. The trial was stopped for safety reasons after the enrollment of 451 patients. Mortality was 47% in the dexamethasone group and 41% in the placebo group by 10 weeks (hazard ratio in the dexamethasone group, 1.11; 95% confidence interval [CI], 0.84 to 1.47; P=0.45) and 57% and 49%, respectively, by 6 months (hazard ratio, 1.18; 95% CI, 0.91 to 1.53; P=0.20). The percentage of patients with disability at 10 weeks was higher in the dexamethasone group than in the placebo group, with 13% versus 25% having a prespecified good outcome (odds ratio, 0.42; 95% CI, 0.25 to 0.69; P<0.001). Clinical adverse events were more common in the dexamethasone group than in the placebo group (667 vs. 494 events, P=0.01), with more patients in the dexamethasone group having grade 3 or 4 infection (48 vs. 25 patients, P=0.003), renal events (22 vs. 7, P=0.004), and cardiac events (8 vs. 0, P=0.004). Fungal clearance in cerebrospinal fluid was slower in the dexamethasone group. Results were consistent across Asian and African sites. Dexamethasone did not reduce mortality among patients with HIV-associated cryptococcal meningitis and was associated with more adverse events and disability than was placebo. (Funded by the United Kingdom Department for International Development and others through the Joint Global Health Trials program; Current Controlled Trials number, ISRCTN59144167.)Keywords
This publication has 27 references indexed in Scilit:
- Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalJournal of Antimicrobial Chemotherapy, 2013
- Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitisAIDS, 2012
- Timing of Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus (HIV)-Associated Tuberculous MeningitisClinical Infectious Diseases, 2011
- Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trialTrials, 2011
- Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsThe Lancet Infectious Diseases, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter StudyClinical Infectious Diseases, 2009
- Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV‐Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 PatientsClinical Infectious Diseases, 2009
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Glucocorticoids and the Th1/Th2 BalanceAnnals of the New York Academy of Sciences, 2004